Best Income Ideas for 2025: Stocks, Bonds, and Everything in Between
GSK Wins Chinese Nod for Nucala as Chronic Rhinosinusitis Treatment
GSK (GSK.US) "Mubilizumab" has been approved for a new indication in China.
Chronic sinusitis accompanied by nasal polyps is a chronic inflammatory disease of the nasal cavity or sinuses, which can lead to the growth of soft tissues known as nasal polyps, usually characterized by an increase in eosinophil levels.
GlaxoSmithKline (GSK.US) has submitted for the market approval of its ultra-long-acting IL-5 monoclonal antibody in China.
The CDE website shows that GlaxoSmithKline (GSK.US) has applied for the market launch of depemokimab in the country.
Achievements and Progress Heading Into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
Pfizer's Progress on C. Diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Youngman : okay what stocks should I keep an eye on in case this happenes?
Jaguar8 OP Youngman : Posted or tagged
Phuong999 : Which one the best ?
Jaguar8 OP Phuong999 : Hmm whichever gets news and buy pressure.